Weight Loss Outcomes with Retatrutide: Clinical Trial Results and Analysis

Overview

Weight loss is a primary efficacy endpoint in retatrutide’s obesity program. Phase 2 produced weight loss larger than any drug had shown before, and Phase 3 has since confirmed and beaten those results. In December 2025, the TRIUMPH-4 trial became the first Phase 3 readout, reporting up to 28.7% mean weight loss at the 12 mg dose over 68 weeks. The pivotal obesity trial, TRIUMPH-1, followed in May 2026 with 28.3% at 12 mg over 80 weeks in 2,339 adults without diabetes. Below we go through the weight loss data in detail: how large the effect is, how it changes with dose, what happens to body composition, and how many people reach key thresholds.

Phase 2 Obesity Trial: Primary Weight Loss Data

The Phase 2 obesity trial, published by Jastreboff et al. in the New England Journal of Medicine (2023), was a 48-week, randomized, double-blind, placebo-controlled study enrolling 338 adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with at least one weight-related comorbidity. Participants were randomized to placebo, retatrutide 1 mg, 4 mg (starting at 2 mg or at 4 mg), 8 mg (starting at 2 mg or at 4 mg), or 12 mg (starting at 2 mg). Doses were raised every 4 weeks.

Mean Weight Loss at 48 Weeks

Mean percentage change in body weight from baseline at 24 weeks (the primary endpoint) and 48 weeks:

Key Observations

Dose-dependent response: Weight loss rose clearly and steeply with dose, from 1 mg up to 12 mg. The gap between the 8 mg and 12 mg groups was fairly small (~1.4 percentage points), which suggests the dose-response curve was starting to flatten at the top doses, though it had not fully leveled off.

Starting dose: The 4 mg and 8 mg targets were each tested with a 2 mg and a 4 mg starting dose. The published results pool each pair, so the -12.9% sometimes quoted for a “fixed 4 mg” arm is in fact the pooled 4 mg result at 24 weeks, not a separate arm.

Continued weight loss at 48 weeks: In the higher-dose groups, weight was still falling at 48 weeks, so treatment beyond 48 weeks could bring more weight loss. That matches other incretin-based drugs, where maximum weight loss often comes only after 60-72 weeks of treatment.

Phase 3 Results: TRIUMPH-4

The TRIUMPH-4 trial, whose topline results were announced in December 2025, was retatrutide’s first Phase 3 readout. It confirmed that the Phase 2 weight loss results held up, and were in fact beaten, in a larger population. This 68-week, randomized, double-blind, placebo-controlled trial enrolled 445 adults with obesity and knee osteoarthritis.

Mean Weight Loss at 68 Weeks

The 28.7% mean weight loss at the 12 mg dose represents the largest mean weight reduction reported for any pharmacological agent in a Phase 3 clinical trial, exceeding the 24.2% observed at the same dose over 48 weeks in Phase 2.

Pain and Functional Outcomes

TRIUMPH-4 also showed significant improvements in knee osteoarthritis symptoms. WOMAC pain scores were reduced by 74.3-75.8% in the active treatment groups, with 14.1% (9 mg) and 12.0% (12 mg) of participants achieving complete freedom from pain, compared with 4.2% in the placebo group.

Cardiometabolic Benefits

Systolic blood pressure was reduced by up to 14.0 mmHg at the highest dose, and the trial met all primary and key secondary endpoints.

Significance

The TRIUMPH-4 results confirm that the large weight loss seen in Phase 2 was not a quirk of a smaller, more selected population. With longer treatment (68 weeks vs. 48 weeks) and a population that also had knee osteoarthritis, the Phase 3 data show that retatrutide’s weight loss holds up and can be reproduced.

Phase 3 Results: TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3

TRIUMPH-1, the pivotal obesity trial in 2,339 adults without diabetes, reported topline results on May 21, 2026 and was published in the New England Journal of Medicine on September 29, 2026. Mean weight loss at 80 weeks (efficacy estimand) was -19.0% at 4 mg, -25.9% at 9 mg and -28.3% at 12 mg, against -2.2% on placebo; 45.3% of the 12 mg group lost at least 30% of their body weight. In a 104-week extension among participants with a baseline BMI of 35 or more, the 12 mg arm reached -30.3%.

On July 23, 2026, TRIUMPH-2 (obesity with type 2 diabetes) reported -20.8% at 12 mg versus -4.0% on placebo, and TRIUMPH-3 (BMI 35+ with cardiovascular disease) reported -22.6% at 12 mg versus -3.2%, both over 80 weeks.

Responder Analyses (Phase 2)

Weight Loss Thresholds

The share of participants reaching clinically meaningful weight loss thresholds adds useful context beyond the averages:

These responder data stand out. In the 12 mg group, essentially everyone lost at least 5% of their weight, and most lost 15% or more. A sizable minority lost as much as people typically do after bariatric surgery (25% or more).

Individual Variability

Average weight loss was impressive, but individual responses varied. Some participants in the higher-dose groups experienced weight reductions exceeding 30%, while others in the same dose groups achieved more modest results. This spread is typical of weight loss drugs and may reflect differences in genetics, starting metabolism, adherence, diet and physical activity. Researchers are still working out what predicts a strong response.

Weight Loss Trajectory

Over the 48 weeks of treatment, weight loss followed a few clear phases:

Early Phase (Weeks 0-12)

During the first dose-escalation period, weight loss was modest in all groups. That reflects the low starting doses and the time it takes to reach therapeutic drug levels. GI side effects, most common in this period, may have added a little early weight loss, but the main drug effects (lasting appetite reduction and higher energy expenditure) take several weeks of rising doses to fully kick in.

Acceleration Phase (Weeks 12-24)

As participants reached their maintenance doses and steady drug levels, weight loss sped up. This is when the full effects of triple agonism were expected to be working, including GLP-1R/GIPR-driven appetite suppression and GCGR-driven increases in energy expenditure.

Continued Loss Phase (Weeks 24-48)

Weight loss continued past 24 weeks in all active groups, though it slowed gradually as the body neared a new energy balance. In the 8 mg and 12 mg groups, people were still losing significant weight between weeks 36 and 48, so the lowest point may not come until well after 48 weeks of treatment.

Body Composition

DEXA Substudy

No body composition results have been published from the Phase 2 obesity trial. The published DEXA data come from a substudy of the Phase 2 type 2 diabetes trial (NCT04867785), reported by Coskun et al. in The Lancet Diabetes & Endocrinology (2025). Of 189 participants enrolled in the substudy, 103 finished treatment with scans at both baseline and week 36.

Fat Mass vs. Lean Mass

Mean reduction in total fat mass from baseline to week 36:

The authors concluded that the share of weight lost as lean mass was similar to that seen with other obesity treatments. These results come from people with type 2 diabetes after 36 weeks and may not apply to people without diabetes or to longer treatment.

Implications for Muscle Health

Losing lean mass during weight loss, with any treatment, raises questions about effects on muscle function, strength and physical performance. Retatrutide trials did not systematically measure functional outcomes like grip strength, walking speed or exercise capacity, but these are seen more and more as important when judging obesity drugs, especially in older adults, where sarcopenic obesity is a concern.

Comparison Context

Versus Other Pharmacological Therapies

No head-to-head comparison with another obesity medication has yet reported in people without diabetes; TRIUMPH-5 (versus tirzepatide) is still running. In type 2 diabetes, TRANSCEND-T2D-2 compared retatrutide with semaglutide 2 mg directly and reported topline results on October 28, 2026: weight -19.5% (9 mg) and -20.9% (12 mg) versus -9.4% at 80 weeks (not yet peer reviewed). Cross-trial comparisons are always limited by differences in study populations, trial lengths, endpoint definitions and statistical methods. With that caveat, the mean weight loss observed with retatrutide at higher doses (22-24% at 48 weeks) is numerically greater than published Phase 2 and Phase 3 results for:

• Semaglutide 2.4 mg (Wegovy): ~15-17% mean weight loss at 68 weeks in the STEP program
• Tirzepatide 15 mg (Zepbound): ~20-22% mean weight loss at 72 weeks in the SURMOUNT program
• Liraglutide 3.0 mg (Saxenda): ~5-8% mean weight loss at 56 weeks

These cross-trial observations suggest that triple agonism offers an incremental weight loss benefit. The TRIUMPH-4 Phase 3 results (28.7% at 12 mg, 68 weeks) have strengthened this conclusion, though formal head-to-head comparisons remain needed.

Versus Bariatric Surgery

Weight loss in the highest retatrutide dose groups approaches the 25-35% typically reported for bariatric operations such as sleeve gastrectomy and Roux-en-Y gastric bypass. The comparison is striking, but there are important differences: bariatric surgery produces weight loss through permanent anatomical changes that affect absorption and gut hormone profiles, whereas pharmacological weight loss requires continued treatment to maintain effect. The long-term durability of retatrutide-associated weight loss and the trajectory after treatment discontinuation remain to be established.

Clinical Significance of Weight Loss Magnitude

The degree of weight loss achieved with retatrutide has implications beyond the scale:

Metabolic Disease Resolution

Population and clinical data consistently show that the more weight people lose, the more their obesity-related conditions improve. Weight loss of 5-10% produces meaningful improvements in glycemic control, blood pressure, and lipids. Weight loss exceeding 15% is associated with remission of type 2 diabetes in many patients and significant improvements in obstructive sleep apnea, osteoarthritis symptoms, and cardiovascular risk. Weight loss approaching 25% may address conditions that typically respond only to bariatric surgery-level weight reduction.

Health-Related Quality of Life

Substantial weight loss is associated with improvements in physical function, mobility, psychosocial well-being, and health-related quality of life. These patient-reported outcomes were not the main focus of Phase 2 trials, but the Phase 3 TRIUMPH program is expected to study them more fully.

Outstanding Questions

Several questions about retatrutide’s weight loss effects remain to be answered by the Phase 3 program and longer-term studies:

1. Maximum weight loss: TRIUMPH-4 demonstrated 28.7% weight loss at 68 weeks and TRIUMPH-1 28.3% at 80 weeks, with the 12 mg arm reaching 30.3% at 104 weeks in a BMI ≥35 subgroup. Whether weight loss continues further with longer treatment remains to be determined.

2. Weight loss maintenance: What proportion of weight loss is maintained with continued treatment over multiple years? Is there weight regain on therapy, as has been observed with some other agents?

3. Post-discontinuation trajectory: How quickly and completely does weight regain occur after stopping retatrutide? This question is critical for informing treatment duration decisions.

4. Reproducibility: TRIUMPH-1 to -4 have confirmed that the Phase 2 results are reproducible in larger populations, with smaller weight loss in people with type 2 diabetes (TRIUMPH-2) and in people with severe obesity and cardiovascular disease (TRIUMPH-3).

5. Combination approaches: Could retatrutide be combined with other interventions (structured exercise programs, behavioral therapy) to further enhance weight loss or improve body composition?

Summary

Retatrutide’s weight loss data are among the strongest ever reported for an obesity drug. Phase 2 showed mean weight reductions of 22-24% at 48 weeks, and the Phase 3 trials confirmed and beat these results: 28.7% at 12 mg over 68 weeks in TRIUMPH-4 and 28.3% at 12 mg over 80 weeks in TRIUMPH-1. With most participants reaching clinically meaningful thresholds, triple receptor agonism is a significant advance in drug treatment for weight. Longer-term data, head-to-head results against tirzepatide (TRIUMPH-5) and data after stopping treatment are still needed to fully characterize retatrutide’s role in obesity treatment.